AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value TargetsBusiness Wire • 09/13/21
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery ConferenceBusiness Wire • 09/10/21
AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/13/21
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative MedicinesBusiness Wire • 08/04/21
Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of CancerBusiness Wire • 08/03/21
AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in CanadaBusiness Wire • 06/22/21
AbCellera Biologics: My Highest Conviction Pick, With The Longest Potential PayoffSeeking Alpha • 05/31/21
Why AbCellera Stock Crumbled Despite In-Line Royalties For Covid DrugInvestors Business Daily • 05/14/21
AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/14/21
AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic RetinopathyBusiness Wire • 05/06/21
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical TrialsBusiness Wire • 05/04/21